glp-1 usage statistics Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline GLP-1 Agonists Market Report 2025-2033,

Based on the mechanism of action and phase 2 results in obese patients and type 2 diabetes patients, I agree and expect CagriSema to generate 24-27% weight loss

One small study of patients with early, untreated Parkinsons disease given high dose intravenous glutathione twice a day for 30 days showed symptom improvement that lasted for 2-4 months after treatment ended (17)

Current treatments are largely the primary application of disease-modifying treatments, immunosuppressants, immunomodulators, and immune-reconstitution therapies, in addition to symptomatic treatments such as anticholinergics for urinary incontinence and pain medication for neuropathic pain (Dobson and Giovannoni, 2019)

Treatment with GLP-1RA also led to reductions in systolic blood pressure and body weight as well as a slight, sustained increase in heart rate compared to the control arm (15)

Loss of SLC7A11 results in lysosomal hyperacidity and labile iron release, sensitizing cells to ferroptosis

Newer medications such as Keppra and Lamictal are usually better tolerated, presenting a lower risk of affecting liver enzyme levels